Colorectal Cancer | Specialty

Colorectal Cancer Screening and Prevention

January 30th 2015

Multitargeted Drug Slows CRC as Third-Line Therapy

January 21st 2015

Treatment with a multitargeted tyrosine kinase inhibitor led to a small but statistically significant improvement in progression-free survival (PFS) in patients with advanced, previously treated metastatic colorectal cancer.

Latest News & Insight: January 15, 2015

January 15th 2015

Dr. Cremolini on Frontline FOLFOXIRI Plus Bevacizumab in mCRC

January 15th 2015

Chiara Cremolini, MD, discusses findings from the phase III TRIBE trial that combined FOLFOXIRI with bevacizumab as a frontline treatment for patients with metastatic colorectal cancer.

Surveillance Could Be a Viable Option for Select Patients With Rectal Cancer

January 12th 2015

A 'watch and wait' surveillance approach may allow certain patients with rectal cancer to achieve excellent outcomes without immediate surgery.

Higher Vitamin D Levels Improve Survival for Patients With mCRC

January 12th 2015

Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of 8 months longer and experienced greater disease-free survival after their cancer treatment.

Ramucirumab Improves Survival in Second-Line mCRC

January 12th 2015

Second-line treatment with the VEGFR2 inhibitor ramucirumab (Cyramza) combined with standard FOLFIRI extended survival by 1.6 months versus FOLFIRI alone in patients with metastatic colorectal cancer (mCRC), according to results from the phase III RAISE trial.

Expanded RAS Mutation Testing in mCRC

January 1st 2015

2014 Year in Review

January 1st 2015

From Bedside to Bench

November 29th 2014

Based on a current laboratory research project, Zarah Dulce F. Lucas, MD, discusses microRNAs and their potential to predict brain metastases in patients with triple-negative and HER2-positive breast cancer.

Experts Emphasize Therapy Options, Expanded Mutation Testing in mCRC

November 18th 2014

Confusion persists about the best choice of frontline therapy for patients with metastatic colorectal cancer (mCRC) after a landmark clinical trial that was conceived a decade ago to answer that question concluded without a superiority finding

Dr. Holcombe on the Utility of Stool DNA Test for Colon Cancer

November 17th 2014

Randall F. Holcombe, MD, professor, Chief Medical Officer, Cancer, Mount Sinai Health System, discusses key takeaways for a practicing oncologist regarding the stool DNA test for colon cancer.

Making Strides With Microspheres: Trial Aims to Extend SIR-Spheres Usage in CRC Liver Metastases

November 12th 2014

The 5-year survival rate for patients with metastatic colorectal cancer (CRC) remains dismal.

Proactively Managing Treatment-Related Adverse Events in Advanced Colorectal Cancer

November 10th 2014

As new therapies enter the treatment landscape for metastatic disease, the role of the oncology nurse becomes even more critical in educating patients about what side effects to look out for and the importance of reporting any adverse events promptly.

Side Effect Management With Regorafenib in mCRC

November 8th 2014

Second- and Third-Line Therapies in mCRC

November 8th 2014

Goals of Therapy in Metastatic CRC

November 8th 2014

Selecting First-line Treatment in mCRC

November 8th 2014

Latest News & Insight: November 7, 2014

November 8th 2014

Colorectal Cancer: Right Test, Right Time

November 4th 2014

Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease, with molecular features defining emerging subtypes. Understanding which tests to order in which cases can better direct care for our patients. Increasingly, panel testing has advantages over individual genetic testing.